iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed drug candidates include iCo-007, an anti-sense inhibitor that is in Phase II clinical trial for the treatment of diabetic macular edema; iCo-008 (Bertilimumab), a monoclonal antibody, which is in Phase II clinical trial to treat patients with moderate-to-severe ulcerative colitis; and iCo-009, an experimental oral formulation of Amphotericin B that is in pre-clinical stage for the treatment of systemic fungal infections and parasitical infections. The company has partnership arrangements with Isis Pharmaceuticals Inc. to develop and commercialize iCo-007; MedImmune Limited and Immune Pharmaceuticals Corp. to develop and commercialize iCo-008; and the University of British Columbia for the development of iCo-009, as well as a research collaboration agreement with Juvenile Diabetes Research Foundation (JDRF) to support the Phase II clinical trial of iCo-007. iCo Therapeutics Inc. was founded in 2005 and is headquartered in Vancouver, Canada.
ico therapeutics inc (ICOTF:OTC US)
760-777 Hornby Street
Vancouver, BC V6Z 1S4
|No competitor information is available for ICOTF.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Post a JobJobs
- Thomasville, GA | Flowers FoodsPosted: Jun 07
- San Francisco, CA | YelpPosted: Jun 06
- San Francisco, CA | PeoplematterPosted: Jun 06
- Orlando, FL | Consult SoftPosted: May 22
Sponsored Financial Commentaries
To contact ICO THERAPEUTICS INC, please visit www.icotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.